1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Kyprolis ENDEAVOR data signal a changing of the guard for multiple myeloma treatment

 
• By Daniel Chancellor

Amgen revealed more data from the ENDEAVOR study that further demonstrate Kyprolis's (carfilzomib; Amgen/Ono Pharmaceutical) superiority to Velcade (bortezomib; Takeda/Johnson & Johnson) as a second-line treatment for relapsed multiple myeloma.

Amgen revealed more data from the ENDEAVOR study that further demonstrate Kyprolis's (carfilzomib; Amgen/Ono Pharmaceutical) superiority to Velcade (bortezomib; Takeda/Johnson & Johnson) as a second-line treatment for relapsed multiple myeloma.

As suggested by Datamonitor Healthcare in its ASCO 2015 Conference Review, the drug could surpass Velcade to become the multiple myeloma market leader if Amgen can also secure a first-line label expansion for Kyprolis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.